| Literature DB >> 34314737 |
Lama Bou-Karroum1, Joanne Khabsa2, Mathilda Jabbour3, Nadeen Hilal3, Zeinab Haidar2, Pamela Abi Khalil2, Rima Abdul Khalek4, Jana Assaf5, Gladys Honein-AbouHaidar6, Clara Abou Samra5, Layal Hneiny7, Sameh Al-Awlaqi8, Johanna Hanefeld9, Fadi El-Jardali1, Elie A Akl10, Charbel El Bcheraoui11.
Abstract
OBJECTIVES: To map travel policies implemented due to COVID-19 during 2020, and conduct a mixed-methods systematic review of health effects of such policies, and related contextual factors.Entities:
Keywords: COVID-19; Outbreak; Quarantine; Screening; Travel restrictions
Mesh:
Year: 2021 PMID: 34314737 PMCID: PMC8310423 DOI: 10.1016/j.jinf.2021.07.017
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072
Countries included in policy mapping.
| Europe | Asia | MENA | America | Africa | Australia |
|---|---|---|---|---|---|
| UKFranceGermany SwedenFinlandGreeceSpainItalyThe Netherland | ChinaTaiwanHong KongJapanSingapore | KSAUAEQatarLebanon | USCanadaBrazilChileMexico | NigeriaLiberiaSierra LeonGuineaKenyaSouth Africa | AustraliaNew Zealand |
Fig. 1Travel policies adopted by 31 countries over the period (January 2020 – December 2020) We observed some differences in travel policies across regions (Fig. 2). For example, while Australia was stricter in imposing total border closure across the one-year period, Europe was less strict.
Fig. 2Travel policies adopted by 31 countries across 6 regions over the period (January 2020 – December 2020).
Fig. 3PRISMA flowchart.
Characteristics of included studies (N=69).
| Type of assessment | ||
|---|---|---|
| Effectiveness studies | 65 | 94% |
| Contextual factors | 4 | 6% |
| Modeling Studies | 50 | 72% |
| Observational Studies | 19 | 28% |
| Border closure | 48 | 70% |
| Quarantine of travelers | 9 | 13% |
| Screening of travelers | 5 | 7% |
| More than one travel policy | 7 | 10% |
| More than one country | 22 | 32% |
| China | 16 | 23% |
| Hypothetical | 8 | 12% |
| South Korea | 5 | 7% |
| Hong Kong | 3 | 4% |
| Australia | 2 | 3% |
| Taiwan | 2 | 3% |
| Other | 11 | 16% |
| Spread across countries and regions | 26 | 38% |
| Outbreak progression | 17 | 25% |
| Number of cases in the community | 15 | 22% |
| Number of cases detected among travelers | 6 | 9% |
| Critical cases and mortality | 5 | 7% |
| Imported diseases | 1 | 1% |
| Reported as funded | 39 | 57% |
| Reported as not funded | 18 | 26% |
| Not reported | 12 | 17% |
| Reported as no conflict of interest | 58 | 84% |
| Reported as conflict of interest | 10 | 14% |
| Not reported | 1 | 1% |
More than option can apply.
Outcome measurements.
| Outcome of interest | Measurements reported by individual studies |
|---|---|
| Spread across countries and regions | Network density Network connectedness COVID-19 cases avoided in a certain countryRisk flow of importation and exportation of COVID-19Epidemic strength (EPS)Spatial spillovers and cross-country spillovers Rate of importation of COVID-19Contribution of imported COVID-19 cases to total casesDelaying the spread |
| Outbreak progression | Effective reproductive number (R)Outbreak pattern across countriesEpidemic sizeEpidemic peakRisk of major outbreaksTime-varying reproduction number (Rt)Gain time of outbreak emergenceArrival time of COVID-19 in other citiesDelaying the epidemic peakDelay case importationDelay of outbreak |
| Number of cases in the community | Existing COVID-19 casesConfirmed COVID-19 casesnumber of COVID-19 cases per millionCumulative number of COVID-19 casesCumulative incidence of COVID-19Number of COVID-19 cases per 10,000 people |
| Number of cases detected among travelers | Number of COVID-19 cases detected among quarantined travelersNumber of cases detected among travelers |
| Critical cases and mortality | Overall mortalityPer-capita mortality from COVID-19COVID-19 mortalityFatality rate |
| Imported diseases | Nationally notifiable diseases |
Comparisons of interest.
| Intervention | |||||
|---|---|---|---|---|---|
| Border closure | Screening of travelers | Quarantine of travelers | A travel policy | ||
| Comparator | 7 observational(very low - low certainty)24 modeling | ||||
| 0 observational3 modeling | |||||
| 4 observational(low certainty)2 modeling | |||||
| 2 observational(low certainty)13 modeling | 0 observational2 modeling | 0 observational1 modelling | |||
| 0 observational3 modeling | |||||
Comparison with similar reviews.
| This review | Burns et al. | Grepin et al. | |
|---|---|---|---|
| Qualitative evidence | Planned to include | Not considered | Not considered |
| Contextual factors | Included | Not considered | Not considered |
| Last date of search | December 27, 2020 | 13 November, 2020 | June 1, 2020 |
| Type of studies included | Only published studies | Preprints and published | Preprints and published |
| Number of included studies | |||
| Phase of the pandemic | Any phase | Any phase | Early phases |
| Disease(s) addressed | COVID-19 | COVID-19 (25 studies)SARSMERS | COVID-19 |
| Policy mapping | Yes | No | No |